{"seq": 1, "variant": "control", "cmd": "pm quick --max 200 personalized dosimetry Lu-PSMA radioligand therapy -v", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "Searching PubMed: \"personalized dosimetry Lu-PSMA radioligand therapy\" (max 200)...\nFetching batch 1 (34 PMIDs)...\n", "elapsed_s": 1.489, "ts": 1771593273.027606}
{"seq": 2, "variant": "control", "cmd": "pm quick --max 200 personalized dosimetry Lu-PSMA radioligand therapy", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "", "elapsed_s": 1.882, "ts": 1771593282.6771667}
{"seq": 3, "variant": "control", "cmd": "pm filter --year 2023- --has-abstract", "exit_code": 0, "stdin_lines": 34, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "", "elapsed_s": 0.316, "ts": 1771593298.3040993}
{"seq": 4, "variant": "control", "cmd": "pm quick --max 200 Lu-PSMA dosimetry", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41713513\", \"title\": \"Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated \u03b3-Sensor Network.\", \"authors\": [\"Lall Rahul\", \"Evans Michael\", \"Seo Youngho\", \"Niknejad Ali\", \"Anwar Mekhail\"], \"journal\": \"International journal of radiation oncology, biology, physics\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need due to significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Towards this goal, here we present a high temporal-resolution activity reconstruction method demonstrated on preclinical prostate cancer models. Utilizing a priori knowledge of tumor locations from a pretherapy scan (e.g. PET/CT), we have developed a low-cost, sparse sensor network to reconstruct the real-time tumor and OAR activity in preclinical cancer models. The proposed system was successfully validated1 with a small custom phantom filled with [177Lu]Lu-PSMA-617 and (2) with 4 mice models, bearing varying numbers of tumors from two human prostate cancer cell lines (PC3-PIP, PC3-flu), to which [177Lu]Lu-PSMA-617 RPT was administered. Uncollimated \u03b3 counts using the developed network were acquired outside of the mouse at 10 minutes post-injection (m.p.i), 6 hours, 12 hours, 24 hours, and 48 hours post-injection (h.p.i). The developed system's total tumor activity and percent injected activity per milliliter of tissue (%IA/mL) reconstruction in tumors, kidneys, and bladders is highly linear with the total tumor activity (R2=0.991) and %IA/mL (R2=0.994) from state-of-art small-animal SPECT. Acquisition and reconstruction were performed at a 1-minute temporal resolution, greater than 30 times faster than conventional small-animal SPECT ima", "stderr": "", "elapsed_s": 2.251, "ts": 1771593707.350662}
{"seq": 5, "variant": "control", "cmd": "pm quick --max 200 Lu-PSMA dosimetry", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41713513\", \"title\": \"Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated \u03b3-Sensor Network.\", \"authors\": [\"Lall Rahul\", \"Evans Michael\", \"Seo Youngho\", \"Niknejad Ali\", \"Anwar Mekhail\"], \"journal\": \"International journal of radiation oncology, biology, physics\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need due to significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Towards this goal, here we present a high temporal-resolution activity reconstruction method demonstrated on preclinical prostate cancer models. Utilizing a priori knowledge of tumor locations from a pretherapy scan (e.g. PET/CT), we have developed a low-cost, sparse sensor network to reconstruct the real-time tumor and OAR activity in preclinical cancer models. The proposed system was successfully validated1 with a small custom phantom filled with [177Lu]Lu-PSMA-617 and (2) with 4 mice models, bearing varying numbers of tumors from two human prostate cancer cell lines (PC3-PIP, PC3-flu), to which [177Lu]Lu-PSMA-617 RPT was administered. Uncollimated \u03b3 counts using the developed network were acquired outside of the mouse at 10 minutes post-injection (m.p.i), 6 hours, 12 hours, 24 hours, and 48 hours post-injection (h.p.i). The developed system's total tumor activity and percent injected activity per milliliter of tissue (%IA/mL) reconstruction in tumors, kidneys, and bladders is highly linear with the total tumor activity (R2=0.991) and %IA/mL (R2=0.994) from state-of-art small-animal SPECT. Acquisition and reconstruction were performed at a 1-minute temporal resolution, greater than 30 times faster than conventional small-animal SPECT ima", "stderr": "", "elapsed_s": 2.274, "ts": 1771593716.0128353}
{"seq": 6, "variant": "control", "cmd": "pm quick --max 200 PSMA radioligand therapy prostate cancer", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41714269\", \"title\": \"Review of radiopharmaceutical therapy in prostate cancer.\", \"authors\": [\"Miller Sean R\", \"Dewaraja Yuni\", \"Rowe Steven P\", \"Reichert Zachery R\", \"Viglianti Benjamin L\"], \"journal\": \"Urologic oncology\", \"year\": \"2026\", \"date\": \"2026-02-18\", \"abstract\": \"Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the advantages of systemic therapy with targeted radiation. The 2 currently FDA approved agents are 223Ra and 177Lu-PSMA-617 which have both demonstrated an overall survival advantage. In this review we will discuss the approved agents, their similarities and differences, treatment sequencing, combinations with other therapies, as well as future directions of this promising field.\", \"doi\": \"10.1016/j.urolonc.2026.111030\"}\n{\"pmid\": \"41701883\", \"title\": \"Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center.\", \"authors\": [\"Pouliot Fr\u00e9d\u00e9ric\", \"Lodde Michele\", \"Besan\u00e7on Marjorie\", \"Castonguay Vincent\", \"Morin-Coulombe Antoine\", \"Fradet Vincent\", \"Fradet Yves\", \"Lacombe Louis\", \"L\u00e9vesque \u00c9ric\", \"Marcoux Nicolas\", \"Toren Paul\", \"April Genevi\u00e8ve\", \"Arsenault Fr\u00e9d\u00e9ric\", \"Beaulieu Alexis\", \"Singbo Narcisse\", \"Veilleux C\u00e9line\", \"Tremblay-Boily M\u00e9lanie\", \"Tremblay Vincent\", \"Buteau Fran\u00e7ois-Alexandre\", \"Beauregard Jean-Mathieu\"], \"journal\": \"Canadian Urological Association journal = Journal de l'Association des urologues du Canada\", \"year\": \"2026\", \"date\": \"2026-02-13\", \"abstract\": \"We aimed to evaluate the efficacy and safety of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) following approval in the real-world Canadian clinical context. Data on the first 50 patients with mCRPC who were treated with lutetium-177-PSMA-617 at a single center in Quebe", "stderr": "", "elapsed_s": 2.693, "ts": 1771593724.3358886}
{"seq": 7, "variant": "control", "cmd": "pm quick --max 200 177Lu PSMA therapy dosimetry", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41713513\", \"title\": \"Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated \u03b3-Sensor Network.\", \"authors\": [\"Lall Rahul\", \"Evans Michael\", \"Seo Youngho\", \"Niknejad Ali\", \"Anwar Mekhail\"], \"journal\": \"International journal of radiation oncology, biology, physics\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need due to significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Towards this goal, here we present a high temporal-resolution activity reconstruction method demonstrated on preclinical prostate cancer models. Utilizing a priori knowledge of tumor locations from a pretherapy scan (e.g. PET/CT), we have developed a low-cost, sparse sensor network to reconstruct the real-time tumor and OAR activity in preclinical cancer models. The proposed system was successfully validated1 with a small custom phantom filled with [177Lu]Lu-PSMA-617 and (2) with 4 mice models, bearing varying numbers of tumors from two human prostate cancer cell lines (PC3-PIP, PC3-flu), to which [177Lu]Lu-PSMA-617 RPT was administered. Uncollimated \u03b3 counts using the developed network were acquired outside of the mouse at 10 minutes post-injection (m.p.i), 6 hours, 12 hours, 24 hours, and 48 hours post-injection (h.p.i). The developed system's total tumor activity and percent injected activity per milliliter of tissue (%IA/mL) reconstruction in tumors, kidneys, and bladders is highly linear with the total tumor activity (R2=0.991) and %IA/mL (R2=0.994) from state-of-art small-animal SPECT. Acquisition and reconstruction were performed at a 1-minute temporal resolution, greater than 30 times faster than conventional small-animal SPECT ima", "stderr": "", "elapsed_s": 2.94, "ts": 1771593732.167293}
{"seq": 8, "variant": "control", "cmd": "pm filter --year 2023- --has-abstract", "exit_code": 0, "stdin_lines": 422, "stdout": "{\"pmid\": \"41713513\", \"title\": \"Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated \u03b3-Sensor Network.\", \"authors\": [\"Lall Rahul\", \"Evans Michael\", \"Seo Youngho\", \"Niknejad Ali\", \"Anwar Mekhail\"], \"journal\": \"International journal of radiation oncology, biology, physics\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need due to significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Towards this goal, here we present a high temporal-resolution activity reconstruction method demonstrated on preclinical prostate cancer models. Utilizing a priori knowledge of tumor locations from a pretherapy scan (e.g. PET/CT), we have developed a low-cost, sparse sensor network to reconstruct the real-time tumor and OAR activity in preclinical cancer models. The proposed system was successfully validated1 with a small custom phantom filled with [177Lu]Lu-PSMA-617 and (2) with 4 mice models, bearing varying numbers of tumors from two human prostate cancer cell lines (PC3-PIP, PC3-flu), to which [177Lu]Lu-PSMA-617 RPT was administered. Uncollimated \u03b3 counts using the developed network were acquired outside of the mouse at 10 minutes post-injection (m.p.i), 6 hours, 12 hours, 24 hours, and 48 hours post-injection (h.p.i). The developed system's total tumor activity and percent injected activity per milliliter of tissue (%IA/mL) reconstruction in tumors, kidneys, and bladders is highly linear with the total tumor activity (R2=0.991) and %IA/mL (R2=0.994) from state-of-art small-animal SPECT. Acquisition and reconstruction were performed at a 1-minute temporal resolution, greater than 30 times faster than conventional small-animal SPECT ima", "stderr": "", "elapsed_s": 0.228, "ts": 1771593757.1605613}
